Clinical trial · Observational
Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy
Quality of Life Analysis of Prostate Cancer Patient's Therapy
NCT00692874CI-TRIAL-00004179AZTEK EXTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open label, non-interventional quality of life analysis for Zoladex treated prostate cancer patients by investigator's questionnaire
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Elements of a general and three disease-specific investigator questionnaire
- timeFrame
- Quarterly (plus or minus 3 days )
Secondary outcomes (1)
- measure
- Investigator Assessment Report
- timeFrame
- Yearly (plus or minus 1 week )
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Provision of informed consent * Early or locally-advanced prostate cancer patients on androgen deprivation therapy * Investigators are requested to recruit patients only with at least 1 month prior Zoladex treatment. Exclusion Criteria: * Allergy to substance of medication * Prostate cancer patients with advanced disease
References
Publications (0)
Data not yet available
No reference posted for this study.